aTyr Pharma | LIFE - Operating Expenses


aTyr Pharma reported $26.94M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Ardelyx USD 105.66M 6.4M Sep/2025
aTyr Pharma USD 26.94M 6.63M Sep/2025
Biogen USD 1.88B 81.4M Sep/2025
Bristol-Myers Squibb USD 18.55B 10.06B Sep/2025
Cipla INR 60.98B 1.06B Dec/2025
Clal Biotechnology ILS 5.15M 9.47M Dec/2022
Compugen USD 9.78M 90K Sep/2025
CSL USD 2.87B 2.85B Jun/2025
Galapagos EUR 112.83M 9.48M Sep/2025
GlaxoSmithKline GBP 5.76B 203M Sep/2025
Grifols EUR 1.77B 22.04M Sep/2025
Novartis USD 9.86B 115M Sep/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
United Therapeutics USD 6.59B 6.07B Sep/2025